Alcon Publishes Agenda for 2024 Annual General Meeting
Alcon welcomes its shareholders to its second in-person AGM In addition to the regular agenda items, shareholders to vote on the Report on Non-Financial Matters... Read more.
Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024
The company is also presenting two trial-in-progress posters for its Phase 1 clinical-stage programs targeting KRAS G12V at the conference BOSTON–(BUSINESS... Read more.
Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma
Data published today by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School to be presented at the American Association of Cancer Research... Read more.
Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
— First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically... Read more.
Notice of Injunction Prohibiting Hytera From Selling or Distributing Any Products Containing Two-Way Radio Technology
SHENZHEN, China–(BUSINESS WIRE)–The U.S. District Court for the Northern District of Illinois has temporarily enjoined Hytera Communications Corp., Ltd.,... Read more.
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
– Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia – SHASTA-3... Read more.
CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024
New data support the feasibility of machine learned algorithms to detect elevated left ventricular end-diastolic pressure (LVEDP) Data collected using the CorVista... Read more.
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
– Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent... Read more.
Angelalign Announces Solid Progress in 2023
SHANGHAI–(BUSINESS WIRE)–On March 19, 2024, Angelalign Technology Inc. (“Angelalign” or the “Company”) announced solid progress in 2023 with... Read more.
egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference
– Study Led by Philippe Généreux, MD, and Colleagues was Presented Today at the 2024 ACC Annual Meeting – – Key Findings Demonstrate Untreated... Read more.